HomeAI · summaries
Storia in 9 fonti
AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push
AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Roche wants the best of both worlds with amylin-incretin combo strategy
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly…
- ·
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
